COMPARISON OF PATIENT, ONCOLOGIST, AND ONCOLOGY NURSE PREFERENCES FOR ATTRIBUTES OF DRUG THERAPY IN ADVANCED MELANOMA

被引：0
|
作者：
Liu, F. X. [1 ]
Witt, E. A. [2 ]
Ebbinghaus, S. [1 ]
Beyer, DiBonaventura G. [2 ]
Basurto, E. [2 ]
Joseph, R. W. [3 ]
机构：
[1] Merck & Co Inc, N Wales, PA USA
[2] Kantar Hlth, Princeton, NJ USA
[3] Mayo Clin, Jacksonville, FL 32224 USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PP1
引用
收藏
页码：A11 / A11
页数：1
相关论文
共 50 条
  • [41] Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example From Advanced Melanoma
    Tilden, Dominic
    Sierakowski, Will
    Cottrell, Suzi
    Kim, Hansoo
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 146 - 146
  • [42] Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis
    Mahadevia, PJ
    Shah, S
    Leibman, C
    Kleinman, L
    O'Dowd, L
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2004, 93 (04) : 345 - 350
  • [43] Hyperprogression or Pseudoprogression during Therapy of advanced Melanoma with Immune Checkpoint Inhibitors - A Patient Analysis
    Ziemer, M.
    Kirsten, H.
    Mentzel, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 79 - 79
  • [44] Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
    Kambayashi, Yumi
    Ohuchi, Kentaro
    Chiba, Hiromu
    Tamabuchi, Erika
    Nagasawa, Tasuku
    Asano, Yoshihide
    Fujimura, Taku
    CASE REPORTS IN ONCOLOGY, 2022, 15 (02): : 469 - 472
  • [45] DEVELOPING ATTRIBUTES AND ATTRIBUTE-LEVELS FOR A DISCRETE CHOICE EXPERIMENT ON LUNG CANCER PATIENT'S PREFERENCES FOR DRUG THERAPIES
    Monteiro, A.
    Santos, M.
    Fontes, L. S.
    VALUE IN HEALTH, 2017, 20 (05) : A116 - A116
  • [46] Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling
    Maculaitis, Martine C.
    Liu, Xianchen
    Will, Oliver
    Hanson, Madelyn
    McRoy, Lynn
    Berk, Alexandra
    Crastnopol, Melissa
    PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 2201 - 2214
  • [47] Optimizing drug therapy in patients with advanced dementia: A patient-centered approach
    Molist Brunet, N.
    Sevilla-Sanchez, D.
    Amblas Novellas, J.
    Codina Jane, C.
    Gomez-Batiste, X.
    McIntosh, J.
    Espaulella Panicot, J.
    EUROPEAN GERIATRIC MEDICINE, 2014, 5 (01) : 66 - 71
  • [48] Patient versus physician preferences for lipid-lowering drug therapy: A discrete choice experiment
    Zhang, Lingli
    Chen, Jiali
    Cao, Zhaoliu
    Zhang, Mengdie
    Ma, Rui
    Zhang, Pei
    Yao, Guiqing
    Li, Xin
    HEALTH EXPECTATIONS, 2024, 27 (02)
  • [49] Comparison between Canadian and British oncology drug review recommendations and their impact on patient access.
    Smith, Matthew K.
    Khan, Omar Farooq
    Yip, Steven
    Tang, Patricia A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] A COMPARISON OF PATIENT AND GENERAL-POPULATION UTILITY VALUES FOR ADVANCED MELANOMA IN HEALTH ECONOMIC MODELLING
    Batty, A.
    Winn, B.
    Lebmeier, M.
    Rowen, D.
    Lee, D.
    VALUE IN HEALTH, 2012, 15 (07) : A285 - A285
12345